The firm plans to submit CMC data for DTX401 informed by the FDA's observations related to an application for its Sanfilippo syndrome type A gene therapy.

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

NEW YORK – Radiopharmaceutical company Nuclidium has raised $99 million in Series B financing to advance its copper-61 and copper-67 theranostics, the firm announced Thursday. The round was led by ...

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

NEW YORK – XyloCor Therapeutics on Thursday said it has treated the first patient with XC001 (encoberminogene rezmadenovec), its gene therapy for coronary artery disease and refractory angina, within ...

NEW YORK – A metastatic melanoma patient with a novel biomarker who received Repare Therapeutics' ATR inhibitor camonsertib within a Phase I/II trial had an exceptional response, spurring interest in ...

The firm will pick two lead agents targeting PSMA and CLDN18.2 later this year and a third STEAP1-targeting drug next year.

NEW YORK – CAR T-cell therapy developer Cargo Therapeutics earlier this week announced it will be bought by Concentra Biosciences. Concentra will acquire Cargo for $4.379 in cash per share of its ...

NEW YORK – Atsena Therapeutics is preparing to test the activity of its gene therapy for X-linked retinoschisis (XLRS) in a pivotal cohort in an ongoing clinical trial. The firm on Wednesday said it ...

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.